Description
Buy 2 Get 1 Free Blend CJC 1295 NO DAC 2mg with Ipamorelin 2mg :
| Unit Size | 4 mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.71% Nominal Target: 2 mg CJC 1295 NO DAC + 2 mg Ipamorelin |
| Sequence (CJC 1295 NO DAC) | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu- Ser-Ala-Arg-Lys-Leu–Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Sequence (IPAMORELIN) | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Formula (CJC 1295 NO DAC) |
C152H252N44O42 |
| Molecular Formula (IPAMORELIN) | C38H49N9O5 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized Blend CJC 1295 NO DAC with Ipamorelin is stable at roomTemperature for 90 days, however it is best to store in a freezer below – 8c for any extended period of time. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
Blend CJC-1295 NO-DAC 2mg with Ipamorelin 2mg
View Research Overview & References
This blend combines two synthetic peptides: CJC-1295 and ipamorelin. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for its interaction with the GHRH receptor. It consists of 30 amino acids with a molecular weight of 3647.16 g/mol. This formulation is CJC-1295 without DAC, meaning it does not contain the drug affinity complex (DAC) used to prolong its half-life.1
Ipamorelin is a synthetic hexapeptide studied for its interaction with the growth hormone secretagogue receptor (GHS-R) in the anterior pituitary gland. Although its structure differs from ghrelin, ipamorelin is studied for functional similarities. It consists of 6 amino acids with a molecular weight of 711.39 g/mol.2 Together, CJC-1295 and ipamorelin are studied for their combined effects on growth hormone-related signaling through two different receptors, of interest for research into receptor synergy.
Animal Model Research
Animal studies have examined both peptides’ effects on bone-related signaling markers and insulin-like growth factor 1 (IGF-1) signaling. Ipamorelin has been studied for its effects on bone mineral content in animal models, while CJC-1295 has been studied for its effects on osteoblast activity markers through IGF-1-related signaling.1,3 Both peptides have also been studied for their effects on insulin-related signaling in pancreatic tissue in animal models.
Important Notice
This product is intended exclusively for in vitro and in vivo (animal) laboratory research and is not for human or animal use or consumption. All findings referenced here are based on in vitro research or animal models, and have not been evaluated for safety or efficacy in humans or animals. This product is strictly for laboratory use to explore biochemical and physiological mechanisms under controlled experimental conditions. Additional research is needed beyond the laboratory research setting.
Product Information
Blue Sky Peptide’s Blend CJC-1295 NO-DAC with Ipamorelin is available as a white lyophilized powder, with a concentration of 4 mg per vial.
References
1. Alba M, Fintini D, Sagazio A, Lawrence B, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-1294.
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-561.
3. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-577.
